Stenting cholesterol-blocked arteries in the brain appears to reduce recurrent stroke risk in patients with intracranial atherosclerotic disease (ICAD), one-year results of the WOVEN* trial, presented at the International Stroke Conference (ISC) 2020, have shown.
Adding cilostazol to other antiplatelet agents could potentially reduce in-stent restenosis (ISR) among patients with carotid artery stenosis who undergo carotid artery stenting (CAS), according to results of the CAS-CARE* trial presented at ISC 2020.
outperformed warfarin in preventing ischaemic events regardless of prior stroke,
transient ischaemic attack (TIA), or thromboembolic event (TE) in patients with
atrial fibrillation (AF) with recent acute coronary syndrome (ACS) or percutaneous
coronary intervention (PCI), a
prespecified secondary analysis of the AUGUSTUS trial has shown.
The eicosapeptide nerinetide did not improve outcomes in patients with large vessel occlusion-related acute ischaemic stroke who underwent endovascular thrombectomy (EVT). However, patients not treated with alteplase appeared to derive some benefit, results from the multinational ESCAPE-NA1* trial showed.
Prompt treatment with tranexamic acid may reduce intracerebral haemorrhage (ICH) growth in patients with ongoing bleeding, though the timing of treatment appears to be key to improved outcomes, according to a study presented at ISC 2020.
The lower 0.25 mg/kg dose of the thrombolytic tenecteplase may be sufficient for reperfusion of blocked vessels prior to thrombectomy in patients with ischaemic stroke due to large-vessel occlusion compared with the 0.4 mg/kg dose, according to the EXTEND-IA TNK* Part 2 study presented at the ISC 2020 Meeting.
Skipping intravenous (IV) tissue plasminogen activator (tPA) before mechanical thrombectomy (MT) may have similarly favourable outcomes to using tPA pre-MT in patients with acute stroke, according to the SKIP* study presented at ISC 2020.
Home blood pressure telemonitoring (HBPTM) combined with telephone-based nurse case management (NCM) led to a greater reduction in systolic blood pressure (BP) among minority stroke survivors with uncontrolled hypertension than HBPTM alone, according to a study presented at ISC 2020.
For the first time, surgeons have successfully used a robot to treat brain aneurysm, a study presented at ISC 2020 has shown. This would eventually allow for remote robotic surgery in patients with limited or no access to endovascular treatments currently.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.